Mucosal adjuvants and long-term memory development with special focus on CTA1-DD and other ADP-ribosylating toxins

Mucosal Immunology

Volumn 3, Issue 6, 2010, Pages 556-566

  Lycke, N ^a   Bemark, M ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; ANTHRAX VACCINE; B LYMPHOCYTE RECEPTOR; CD40 ANTIGEN; CD40 LIGAND; CHOLERA TOXIN; COMPLEMENT COMPONENT C3B RECEPTOR; COMPLEMENT RECEPTOR; COMPLEMENT RECEPTOR 2; CPG OLIGODEOXYNUCLEOTIDE; CTA1 DD FUSION PROTEIN; ESCHERICHIA COLI ENTEROTOXIN; ESCHERICHIA COLI HEAT LABILE TOXIN; GANGLIOSIDE GM1 RECEPTOR; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN M; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; INTERLEUKIN 10; INTERLEUKIN 6; LIVE VACCINE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; OVALBUMIN; PHOSPHORYL LIPID A; RECEPTOR PROTEIN; STAT3 PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADENOSINE DIPHOSPHATE RIBOSYLATION; ADJUVANT THERAPY; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN PRESENTING CELL; B LYMPHOCYTE; B LYMPHOCYTE DIFFERENTIATION; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLASS SWITCH RECOMBINATION; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG MEGADOSE; DRUG TARGETING; FOLLICULAR DENDRITIC CELL; GENE REARRANGEMENT; GERMINAL CENTER; HELPER CELL; HUMAN; HYPER IGM SYNDROME; IMMUNOLOGICAL MEMORY; IMMUNOSTIMULATION; INNATE IMMUNITY; INTESTINE LYMPHATIC TISSUE; LAMINA PROPRIA; LYMPHOCYTE PROLIFERATION; MEMORY CELL; MUCOSAL IMMUNITY; NONHUMAN; PEYER PATCH; PLASMA CELL; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; REVIEW; SINGLE DRUG DOSE; SOMATIC HYPERMUTATION; T LYMPHOCYTE; TH1 CELL; TH2 CELL; VACCINATION;

EID: 77958195796     PISSN: 19330219     EISSN: None     Source Type: Journal    
DOI: 10.1038/mi.2010.54     Document Type: Review

References (124)

1. Ahmed, R. & Gray, D. Immunological memory and protective immunity: understanding their relation. Science 272, 54-60 (1996).
2. Amanna, I. J., Carlson, N. E. & Slifka, M. K. Duration of humoral immunity to common viral and vaccine antigens. N. Engl. J. Med. 357, 1903-1915 (2007).
3. Lambrecht, B. N., Kool, M., Willart, M. A. & Hammad, H. Mechanism of action of clinically approved adjuvants. Curr. Opin. Immunol. 21, 23-29 (2009).
4. Tagliabue, A. & Rappuoli, R. Vaccine adjuvants: the dream becomes real. Hum. Vaccin. 4, 347-349 (2008).
5. Kenney, R. T. & Cross, A. S. Adjuvants for the future. In New Generation Vaccines, 4th edn. (Levine, M. M., ed) 250-262 (Informa Healthcare USA, New York, NY, 2010).
6. Galli, G. et al. Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proc. Natl. Acad. Sci. USA 106, 7962-7967 (2009).
7. Castellino, F., Galli, G., Del Giudice, G. & Rappuoli, R. Generating memory with vaccination. Eur. J. Immunol. 39, 2100-2105 (2009).
8. Delgado, M. F. et al. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat. Med. 15, 34-41 (2009).
9. Pulendran, B. Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology. Nat. Rev. Immunol. 9, 741-747 (2009).
10. Harandi, A. M. & Medaglini, D. Mucosal Adjuvants. Curr. HIV Res 8, 330-335 (2010).
11. Lycke, N. Mechanisms of adjuvant action. In Vaccine Adjuvants and Delivery Systems. (Singh, M., ed) 53-79 (Wiley, Hoboken, NJ, 2007).
12. Freytag, L. C., Clements, J. D., Grdic Eliasson, D. & Lycke, N. Use of genetically or chemically detoxified mutants of cholera and Escherichia coli heat-labile enterotoxins as mucosal adjuvants. In New Generation Vaccines, 4th edn. (Levine, M. M., ed) 273-283 (Informa Healthcare USA, New York, NY, 2010).
13. O'Neal, C. J., Amaya, E. I., Jobling, M. G., Holmes, R. K. & Hol, W. G. Crystal structures of an intrinsically active cholera toxin mutant yield insight into the toxin activation mechanism. Biochemistry 43, 3772-3782 (2004).
14. Tangye, S. G. & Tarlinton, D. M. Memory B cells: effectors of long-lived immune responses. Eur. J. Immunol. 39, 2065-2075 (2009).
15. Berek, C., Berger, A. & Apel, M. Maturation of the immune response in germinal centers. Cell 67, 1121-1129 (1991).
16. Schwickert, T. A. et al. In vivo imaging of germinal centres reveals a dynamic open structure. Nature 446, 83-87 (2007).
17. Allen, C. D., Okada, T. & Cyster, J. G. Germinal-center organization and cellular dynamics. Immunity 27, 190-202 (2007).
18. Yu, D., Batten, M., Mackay, C. R. & King, C. Lineage specification and heterogeneity of T follicular helper cells. Curr. Opin. Immunol. 21, 619-625 (2009).
19. Vinuesa, C. G., Sanz, I. & Cook, M. C. Dysregulation of germinal centres in autoimmune disease. Nat. Rev. Immunol. 9, 845-857 (2009).
20. Han, S. et al. Cellular interaction in germinal centers. Roles of CD40 ligand and B7-2 in established germinal centers. J. Immunol. 155, 556-567 (1995).
21. Van Essen, D., Kikutani, H. & Gray, D. CD40 ligand-transduced costimulation of T cells in the development of helper function. Nature 378, 620-623 (1995).
22. Weller, S. et al. CD40-CD40L independent Ig gene hypermutation suggests a second B cell diversification pathway in humans. Proc. Natl. Acad. Sci. USA 98, 1166-1170 (2001).
23. Seifert, M. & Kuppers, R. Molecular footprints of a germinal center derivation of human IgM+ (IgD+) CD27+ B cells and the dynamics of memory B cell generation. J. Exp. Med. 206, 2659-2669 (2009).
24. Tangye, S. G. & Good, K. L. Human IgM+CD27+ B cells: memory B cells or " memory " B cells? J. Immunol. 179, 13-19 (2007).
25. Dogan, I. et al. Multiple layers of B cell memory with different effector functions. Nat. Immunol. 10, 1292-1299 (2009).
26. Weller, S. et al. Somatic diversification in the absence of antigen-driven responses is the hallmark of the IgM+ IgD+ CD27+ B cell repertoire in infants. J. Exp. Med. 205, 1331-1342 (2008).
27. Casola, S. et al. B cell receptor signal strength determines B cell fate. Nat. Immunol. 5, 317-327 (2004).
28. Bergqvist, P., Gardby, E., Stensson, A., Bemark, M. & Lycke, N. Y. Gut IgA class switch recombination in the absence of CD40 does not occur in the lamina propria and is independent of germinal centers. J. Immunol. 177, 7772-7783 (2006).
29. He, B. et al. Intestinal bacteria trigger T cell-independent immunoglobulin A (2) class switching by inducing epithelial-cell secretion of the cytokine APRIL. Immunity 26, 812-826 (2007).
30. Bergqvist, P., Stensson, A., Lycke, N. Y. & Bemark, M. T cell-independent IgA class switch recombination is restricted to the GALT and occurs prior to manifest germinal center formation. J. Immunol. 184, 3545-3553 (2010).
31. Barone, F., Patel, P., Sanderson, J. D. & Spencer, J. Gut-associated lymphoid tissue contains the molecular machinery to support T-celldependent and T-cell-independent class switch recombination. Mucosal. Immunol. 2, 495-503 (2009).
32. Litinskiy, M. B. et al. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat. Immunol. 3, 822-829 (2002).
33. Fang, Y., Xu, C., Fu, Y. X., Holers, V. M. & Molina, H. Expression of complement receptors 1 and 2 on follicular dendritic cells is necessary for the generation of a strong antigen-specific IgG response. J. Immunol. 160, 5273-5279 (1998). (Pubitemid 28267813)
34. Fischer, M. B. et al. Dependence of germinal center B cells on expression of CD21/CD35 for survival. Science 280, 582-585 (1998).
35. Reinhardt, R. L., Liang, H. E. & Locksley, R. M. Cytokine-secreting follicular T cells shape the antibody repertoire. Nat. Immunol. 10, 385-393 (2009).
36. Nurieva, R. I. et al. Generation of T follicular helper cells is mediated by interleukin-21 but independent of T helper 1, 2, or 17 cell lineages. Immunity 29, 138-149 (2008).
37. Anderson, S. M. et al. Taking advantage: high-affinity B cells in the germinal center have lower death rates, but similar rates of division, compared to low-affinity cells. J. Immunol 183, 7314-7325 (2009).
38. Odegard, J. M. et al. ICOS-dependent extrafollicular helper T cells elicit IgG production via IL-21 in systemic autoimmunity. J. Exp. Med. 205, 2873-2886 (2008).
39. Ozaki, K. et al. A critical role for IL-21 in regulating immunoglobulin production. Science 298, 1630-1634 (2002).
40. Vogelzang, A. et al. A fundamental role for interleukin-21 in the generation of T follicular helper cells. Immunity 29, 127-137 (2008).
41. Seder, R. A. & Ahmed, R. Similarities and differences in CD4+ and CD8+ effector and memory T cell generation. Nat. Immunol. 4, 835-842 (2003).
42. Whitmire, J. K. et al. Requirement of B cells for generating CD4+ T cell memory. J. Immunol. 182, 1868-1876 (2009).
43. Crotty, S. et al. Cutting edge: long-term B cell memory in humans after smallpox vaccination. J. Immunol. 171, 4969-4973 (2003).
44. Hammarlund, E. et al. Duration of antiviral immunity after smallpox vaccination. Nat. Med. 9, 1131-1137 (2003).
45. Querec, T. et al. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J. Exp. Med. 203, 413-424 (2006).
46. Querec, T. D. et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat. Immunol. 10, 116-125 (2009).
47. Mamani-Matsuda, M. et al. The human spleen is a major reservoir for long-lived vaccinia virus-specific memory B cells. Blood 111, 4653-4659 (2008).
48. Ahuja, A., Anderson, S. M., Khalil, A. & Shlomchik, M. J. Maintenance of the plasma cell pool is independent of memory B cells. Proc. Natl. Acad. Sci. USA 105, 4802-4807 (2008).
49. Bernasconi, N. L., Traggiai, E. & Lanzavecchia, A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 298, 2199-2202 (2002).
50. Slifka, M. K. & Ahmed, R. Long-lived plasma cells: a mechanism for maintaining persistent antibody production. Curr. Opin. Immunol. 10, 252-258 (1998).
51. Tross, D. & Klinman, D. M. Effect of CpG oligonucleotides on vaccineinduced B cell memory. J. Immunol. 181, 5785-5790 (2008).
52. Kool, M. et al. Cutting edge: alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome. J. Immunol. 181, 3755-3759 (2008).
53. Itano, A. A. & Jenkins, M. K. Antigen presentation to naive CD4 T cells in the lymph node. Nat. Immunol. 4, 733-739 (2003).
54. Iwasaki, A. & Medzhitov, R. Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 5, 987-995 (2004).
55. Fahlen-Yrlid, L. et al. CD11c (high) dendritic cells are essential for activation of CD4+ T cells and generation of specific antibodies following mucosal immunization. J. Immunol. 183, 5032-5041 (2009).
56. Hawiger, D. et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J. Exp. Med. 194, 769-779 (2001).
57. Mempel, T. R., Henrickson, S. E. & Von Andrian, U. H. T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases. Nature 427, 154-159 (2004).
58. Steinman, R. M. Dendritic cells: understanding immunogenicity. Eur. J. Immunol. 37, S53-60 (2007).
59. Manicassamy, S. & Pulendran, B. Modulation of adaptive immunity with Toll-like receptors. Semin. Immunol. 21, 185-193 (2009).
60. Pulendran, B., Banchereau, J., Maraskovsky, E. & Maliszewski, C. Modulating the immune response with dendritic cells and their growth factors. Trends. Immunol. 22, 41-47 (2001).
61. Bonifaz, L. et al. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J. Exp. Med. 196, 1627-1638 (2002).
62. Boscardin, S. B. et al. Antigen targeting to dendritic cells elicits long-lived T cell help for antibody responses. J. Exp. Med. 203, 599-606 (2006).
63. Dudziak, D. et al. Differential antigen processing by dendritic cell subsets in vivo. Science 315, 107-111 (2007).
64. Soares, H. et al. A subset of dendritic cells induces CD4+ T cells to produce IFN-gamma by an IL-12-independent but CD70-dependent mechanism in vivo. J. Exp. Med. 204, 1095-1106 (2007).
65. Lefrancois, L. Development, trafficking, and function of memory T-cell subsets. Immunol. Rev. 211, 93-103 (2006).
66. Sallusto, F., Mackay, C. R. & Lanzavecchia, A. The role of chemokine receptors in primary, effector, and memory immune responses. Annu. Rev. Immunol. 18, 593-620 (2000).
67. Bluestone, J. A. & Abbas, A. K. Natural versus adaptive regulatory T cells. Nat. Rev. Immunol. 3, 253-257 (2003).
68. Baecher-Allan, C. & Anderson, D. E. Immune regulation in tumor-bearing hosts. Curr. Opin. Immunol. 18, 214-219 (2006).
69. Berrih-Aknin, S., Fuchs, S. & Souroujon, M. C. Vaccines against myasthenia gravis. Expert Opin. Biol. Ther. 5, 983-995 (2005).
70. Lewis, D. J. et al. Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS One 4, e6999 (2009).
71. Fan, E. et al. Structural biology and structure-based inhibitor design of cholera toxin and heat-labile enterotoxin. Int. J. Med. Microbiol. 294, 217-223 (2004).
72. Holmgren, J. & Czerkinsky, C. Mucosal immunity and vaccines. Nat. Med. 11, S45-53 (2005).
73. Kawamura, Y. I. et al. Cholera toxin activates dendritic cells through dependence on GM1-ganglioside which is mediated by NF-kappaB translocation. Eur. J. Immunol. 33, 3205-3212 (2003).
74. Rappuoli, R., Pizza, M., Douce, G. & Dougan, G. Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins. Immunol. Today 20, 493-500 (1999).
75. Soriani, M., Bailey, L. & Hirst, T. R. Contribution of the ADP-ribosylating and receptor-binding properties of cholera-like enterotoxins in modulating cytokine secretion by human intestinal epithelial cells. Microbiology 148, 667-676 (2002).
76. Giuliani, M. M. et al. Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity. J. Exp. Med. 187, 1123-1132 (1998).
77. Douce, G. et al. Mucosal immunogenicity of genetically detoxified derivatives of heat labile toxin from Escherichia coli. Vaccine 16, 1065-1073 (1998).
78. Dickinson, B. L. & Clements, J. D. Dissociation of Escherichia coli heatlabile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect. Immun. 63, 1617-1623 (1995).
79. Hagiwara, Y. et al. Effects of intranasal administration of cholera toxin (or Escherichia coli heat-labile enterotoxin) B subunits supplemented with a trace amount of the holotoxin on the brain. Vaccine 19, 1652-1660 (2001).
80. Summerton, N. A. et al. Toward the development of a stable, freeze-dried formulation of Helicobacter pylori killed whole cell vaccine adjuvanted with a novel mutant of Escherichia coli heat-labile toxin. Vaccine 28, 1404-1411 (2010).
81. Braun, M. C., He, J., Wu, C. Y. & Kelsall, B. L. Cholera toxin suppresses interleukin (IL)-12 production and IL-12 receptor beta1 and beta2 chain expression. J. Exp. Med. 189, 541-552 (1999).
82. Cong, Y., Oliver, A. O. & Elson, C. O. Effects of cholera toxin on macrophage production of co-stimulatory cytokines. Eur. J. Immunol. 31, 64-71 (2001).
83. Lavelle, E. C. et al. Effects of cholera toxin on innate and adaptive immunity and its application as an immunomodulatory agent. J. Leukoc. Biol. 75, 756-763 (2004).
84. Lavelle, E. C. et al. Cholera toxin promotes the induction of regulatory T cells specific for bystander antigens by modulating dendritic cell activation. J. Immunol. 171, 2384-2392 (2003).
85. Lycke, N. From toxin to adjuvant: basic mechanisms for the control of mucosal IgA immunity and tolerance. Immunol. Lett. 97, 193-198 (2005).
86. Williamson, E., Westrich, G. M. & Viney, J. L. Modulating dendritic cells to optimize mucosal immunization protocols. J. Immunol. 163, 3668-3675 (1999).
87. Sjöblom-Hallén, A. et al. Gene expression profiling identifies STAT3 as a novel pathway for immunomodulation by cholera toxin adjuvant. Mucosal. Immunol. 3, 374-386 (2010).
88. Melillo, J. A. et al. Dendritic cell (DC)-specific targeting reveals Stat3 as a negative regulator of DC function. J. Immunol. 184, 2638-2645 (2010).
89. Lycke, N. Targeted vaccine adjuvants based on modified cholera toxin. Curr. Mol. Med. 5, 591-597 (2005).
90. La Sala, A. et al. Cholera toxin inhibits IL-12 production and CD8alpha+ dendritic cell differentiation by cAMP-mediated inhibition of IRF8 function. J. Exp. Med. 206, 1227-1235 (2009).
91. Akhiani, A. A. et al. Protection against Helicobacter pylori infection following immunization is IL-12-dependent and mediated by Th1 cells. J. Immunol. 169, 6977-6984 (2002).
92. Grdic, D. et al. The mucosal adjuvant effects of cholera toxin and immune-stimulating complexes differ in their requirement for IL-12, indicating different pathways of action. Eur. J. Immunol. 29, 1774-1784 (1999).
93. Hornquist, E. & Lycke, N. Cholera toxin adjuvant greatly promotes antigen priming of T cells. Eur. J. Immunol. 23, 2136-2143 (1993).
94. Grdic, D. et al. Splenic marginal zone dendritic cells mediate the cholera toxin adjuvant effect: dependence on the ADP-ribosyltransferase activity of the holotoxin. J. Immunol. 175, 5192-5202 (2005).
95. Martin, M., Sharpe, A., Clements, J. D. & Michalek, S. M. Role of B7 costimulatory molecules in the adjuvant activity of the heat-labile enterotoxin of Escherichia coli. J. Immunol. 169, 1744-1752 (2002).
96. Yamamoto, M. et al. Enterotoxin adjuvants have direct effects on T cells and antigen-presenting cells that result in either interleukin-4-dependent or-independent immune responses. J. Infect. Dis. 182, 180-190 (2000).
97. Lycke, N. & Holmgren, J. Intestinal mucosal memory and presence of memory cells in lamina propria and Peyer's patches in mice 2 years after oral immunization with cholera toxin. Scand. J. Immunol. 23, 611-616 (1986).
98. Lycke, N. & Holmgren, J. Long-term cholera antitoxin memory in the gut can be triggered to antibody formation associated with protection within hours of an oral challenge immunization. Scand. J. Immunol. 25, 407-412 (1987).
99. Lycke, N. & Holmgren, J. Adoptive transfer of gut mucosal antitoxin memory by isolated B cells 1 year after oral immunization with cholera toxin. Infect. Immun. 57, 1137-1141 (1989).
100. Vajdy, M. & Lycke, N. Stimulation of antigen-specific T-and B-cell memory in local as well as systemic lymphoid tissues following oral immunization with cholera toxin adjuvant. Immunology 80, 197-203 (1993).
101. Vajdy, M. & Lycke, N. Mucosal memory B cells retain the ability to produce IgM antibodies 2 years after oral immunization. Immunology 86, 336-342 (1995).
102. Vajdy, M. & Lycke, N. Y. Cholera toxin adjuvant promotes long-term immunological memory in the gut mucosa to unrelated immunogens after oral immunization. Immunology 75, 488-492 (1992).
103. Soenawan, E. et al. Maintenance of long-term immunological memory by low avidity IgM-secreting cells in bone marrow after mucosal immunizations with cholera toxin adjuvant. Vaccine 22, 1553-1563 (2004).
104. Schwickert, T. A., Alabyev, B., Manser, T. & Nussenzweig, M. C. Germinal center reutilization by newly activated B cells. J. Exp. Med. 206, 2907-2914 (2009).
105. Benner, R., Hijmans, W. & Haaijman, J. J. The bone marrow: the major source of serum immunoglobulins, but still a neglected site of antibody formation. Clin. Exp. Immunol. 46, 1-8 (1981).
106. Agren, L. C., Ekman, L., Lowenadler, B., Nedrud, J. G. & Lycke, N. Y. Adjuvanticity of the cholera toxin A1-based gene fusion protein, CTA1-DD, is critically dependent on the ADP-ribosyltransferase and Ig-binding activity. J. Immunol. 162, 2432-2440 (1999).
107. Fujihashi, K., Koga, T., Van Ginkel, F. W., Hagiwara, Y. & Mcghee, J. R. A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants. Vaccine 20, 2431-2438 (2002).
108. Levine, M. M. et al. Evaluation in humans of attenuated Vibrio cholerae El Tor Ogawa strain Texas Star-SR as a live oral vaccine. Infect. Immun. 43, 515-522 (1984).
109. Glueck, R. Pre-clinical and clinical investigation of the safety of a novel adjuvant for intranasal immunization. Vaccine 20, S42-44 (2001).
110. Mutsch, M. et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N. Engl. J. Med. 350, 896-903 (2004).
111. Partidos, C. D., Salani, B. F., Pizza, M. & Rappuoli, R. Heat-labile enterotoxin of Escherichia coli and its site-directed mutant LTK63 enhance the proliferative and cytotoxic T-cell responses to intranasally co-immunized synthetic peptides. Immunol. Lett. 67, 209-216 (1999).
112. Agren, L., Lowenadler, B. & Lycke, N. A novel concept in mucosal adjuvanticity: the CTA1-DD adjuvant is a B cell-targeted fusion protein that incorporates the enzymatically active cholera toxin A1 subunit. Immunol. Cell. Biol. 76, 280-287 (1998).
113. Agren, L. C., Ekman, L., Lowenadler, B. & Lycke, N. Y. Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit. J. Immunol. 158, 3936-3946 (1997).
114. Agren, L. et al. The ADP-ribosylating CTA1-DD adjuvant enhances T cell-dependent and independent responses by direct action on B cells involving anti-apoptotic Bcl-2-and germinal center-promoting effects. J. Immunol. 164, 6276-6286 (2000).
115. Eriksson, A. M., Schon, K. M. & Lycke, N. Y. The cholera toxin-derived CTA1-DD vaccine adjuvant administered intranasally does not cause inflammation or accumulate in the nervous tissues. J. Immunol. 173, 3310-3319 (2004).
116. van Ginkel, F. W., Jackson, R. J., Yuki, Y. & Mcghee, J. R. Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J. Immunol. 165, 4778-4782 (2000).
117. Akhiani, A. A., Stensson, A., Schon, K. & Lycke, N. The nontoxic CTA1-DD adjuvant enhances protective immunity against Helicobacter pylori infection following mucosal immunization. Scand. J. Immunol. 63, 97-105 (2006).
118. Andersen, C. S. et al. The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis. Infect. Immun. 75, 408-416 (2007).
119. Cunningham, K. A., Carey, A. J., Lycke, N., Timms, P. & Beagley, K. W. CTA1-DD is an effective adjuvant for targeting anti-chlamydial immunity to the murine genital mucosa. J. Reprod. Immunol. 81, 34-38 (2009).
120. Eliasson, D. G. et al. CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine. Vaccine 26, 1243-1252 (2008).
121. Mcneal, M. M. et al. Intrarectal immunization of mice with VP6 and either LT (R192G) or CTA1-DD as adjuvant protects against fecal rotavirus shedding after EDIM challenge. Vaccine 25, 6224-6231 (2007).
122. Sundling, C. et al. CTA1-DD adjuvant promotes strong immunity against human immunodeficiency virus type 1 envelope glycoproteins following mucosal immunization. J. Gen. Virol. 89, 2954-2964 (2008).
123. Helgeby, A. et al. The combined CTA1-DD/ISCOM adjuvant vector promotes priming of mucosal and systemic immunity to incorporated antigens by specific targeting of B cells. J. Immunol. 176, 3697-3706 (2006).
124. Smith, R. E., Donachie, A. M., Grdic, D., Lycke, N. & Mowat, A. M. Immune-stimulating complexes induce an IL-12-dependent cascade of innate immune responses. J. Immunol. 162, 5536-5546 (1999).